JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 39 No. 5 822-825
© 1998 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vattimo, A.
Right arrow Articles by Lazzi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vattimo, A.
Right arrow Articles by Lazzi, S.

Hürthle Cell Tumor Dwelling in Hot Thyroid Nodules: Preoperative Detection with Technetium-99m-MIBI Dual-Phase Scintigraphy

Angelo Vattimo, Paolo Bertelli, Marcella Cintorino, Luca Burroni, Duccio Volterrani, Alessandra Vella and Stefano Lazzi

Nuclear Medicine Unit, Institute of Pathology, University of Siena, Siena, Italy

Correspondence: For correspondence or reprints contact: Angelo Vattimo, MD, Nuclear Medicine Unitof the University of Siena, Le Scotte Hospital, Viale Bracci, 53100 Siena, Italy.

ABSTRACT

Single injection dual-phase scintigraphy (early and late acquisitions) with 99mTc-MIBI was used to differentiate benign and malignant hot thyroid nodules. Methods: Thirteen euthyroid and two hyperthyroid patients displaying a hot thyroid nodule on the 99mTc scan due to an autonomously functioning thyroid nodule (AFTN) underwent early 15–30 min) and late (3–4 hr) thyroid scintigraphy after the administration of 740–1000 MBq 99mTc-MIBI. Visual scoring was done to assess nodular tracer uptake and retention. In addition, the nodular-to-thyroid (N/T) uptake ratio in the early and late image and the washout rates (WO) from the nodule and thyroidal tissue were measured. All patients underwent thyroid surgery. Results: Histopathology revealed a Hörthle cell tumor in three nodules, a benign adenoma with oxyphilic metaplasia in two nodules and a benign adenoma without oxyphilic cells in the remaining 10 nodules. The Hörthle cell tumor nodules displayed intense and persistent uptake of 99mTc-MIBI (N/T was 2.81 ± 0.52 and 5.53 ± 1.06 in early and late images, respectively; WO from the nodule was 12.33 ± 0.47, WO from the thyroidal tissue was 22.00 ± 3.56). The benign nodules showed intense uptake in the early image and intense uptake to absent retention in the late image (N/T was 2.94 ± 1.31 and 1.62 ± 0.50 in the early and late images, respectively; WO from the nodule was 20.25 ± 2.92, WO from the thyroidal tissue was 20.33 ± 2.92). Conclusion: Single injectiondual-phase 99mTc-MIBI scintigraphy of the thyroid with AFTN can identify nodules as a result of the activity of a Höthle cell tumor, since these tumors cause intense and persistent tracer uptake in contrast with a benign AFTN.

Key Words: thyroid scintigraphy • technetium-99m-sestamibi • ot nodules • Hörthlecells tumor




This article has been cited by other articles:


Home page
JNMHome page
L.-F. de Geus-Oei, G. F.F.M. Pieters, J. J. Bonenkamp, A. H. Mudde, C. P. Bleeker-Rovers, F. H.M. Corstens, and W. J.G. Oyen
18F-FDG PET Reduces Unnecessary Hemithyroidectomies for Thyroid Nodules with Inconclusive Cytologic Results
J. Nucl. Med., May 1, 2006; 47(5): 770 - 775.
[Abstract] [Full Text] [PDF]


Home page
Arch SurgHome page
N. T. Jaskowiak, S. L. Sugg, J. Helke, M. R. Koka, and E. L. Kaplan
Pitfalls of Intraoperative Quick Parathyroid Hormone Monitoring and Gamma Probe Localization in Surgery for Primary Hyperparathyroidism
Arch Surg, June 1, 2002; 137(6): 659 - 669.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1998 by the Society of Nuclear Medicine.